Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor-derived RAC1A159V mutation promotes an immunosuppressive microenvironment that represses response to immune checkpoint inhibitor.

Science advances - 31 Oct 2025

Cai Mingjun, Adam Mike, Duan Xin, Guo Fukun, Zheng Yi

Abstract excerpt

RAC1A159V is a hotspot mutation associated with poor prognosis in several cancers. By gene editing, we generated endogenous homozygous and heterozygous RAC1A159V mutations, which result in up-regulated RAC1 activity and mammalian target of rapamycin (mTOR) signaling. RAC1A159V tumors grow faster than RAC1WT tumors in immune-proficient mice and are resistant to anti-programmed death protein 1 (PD1). Flow cytometry...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Checkpoint Inhibitors
Share to Mechanistic Target of Rapamycin Complex 1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasms

Share to Neuropeptides

Share to Programmed Cell Death 1 Receptor

Share to rac1 GTP-Binding Protein

Share to TOR Serine-Threonine Kinases

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 41160695
DOI: 10.1126/sciadv.aea1212
PMCID: PMC12571076

Genes

RAC1
IFNGR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor-derived RAC1A159V mutation promotes an immunosuppressive microenvironment that represses response to immune checkpoint inhibitor.PMID 41160695Read ↗

Integrated Pan-Cancer Profiling of RAC1: Prognostic, Immunomodulatory, and Therapeutic Resistance InsightsSemantic proximity Read ↗

RAC1: Comprehensive Analysis of Genetic Alteration, Prognostic and Immunological Role Over Tumor ProfilesSemantic proximity Read ↗

Assessment of RACGAP1 as a Prognostic and Immunological Biomarker in Multiple Human Tumors: A Multiomics AnalysisSemantic proximity Read ↗

Rasal1 impairment unleashes anticancer immunity - a focus on T cellsSemantic proximity Read ↗

RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy ResistanceSemantic proximity Read ↗

Hypoxia, Autophagy and Immune Escape in the Tumor Microenvironment: From Mechanisms to Therapeutic TargetingSemantic proximity Read ↗

ROCK1 inhibition primes anti-tumor immunity in EGFR-mutant NSCLC by triggering PD-L1 degradation mediated by SMURF2.Semantic proximity Read ↗

mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasionSemantic proximity Read ↗

The Role of Ras-Associated Protein 1 (Rap1) in Cancer: Bad Actor or Good Player?Semantic proximity Read ↗

Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1.Semantic proximity Read ↗

Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphomaSemantic proximity Read ↗

RAC1-Amplified and RAC1-A159V Hotspot-Mutated Head and Neck Cancer Sensitive to the Rac Inhibitor EHop-016 In Vivo: A Proof-of-Concept StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.